Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
Benzinga Insights 8 months ago
Analyst Ratings
7 analysts have shared their evaluations of CG Oncology (NASDAQ:CGON) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $68.14, along with a high estimate of $75.00 and a low estimate of $61.00. Marking an increase of 14.71%, the current average surpasses the previous average price target of $59.40.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of CG Oncology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | Truist Securities | Raises | Buy | $75.00 | $66.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $73.00 | $61.00 |
| Kelsey Goodwin | Piper Sandler | Raises | Overweight | $70.00 | $55.00 |
| Gregory Renza | Truist Securities | Raises | Buy | $66.00 | $62.00 |
| Robert Driscoll | Wedbush | Announces | Outperform | $70.00 | - |
| Gregory Renza | Truist Securities | Announces | Buy | $62.00 | - |
| Leonid Timashev | RBC Capital | Raises | Outperform | $61.00 | $53.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CG Oncology. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CG Oncology compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into CG Oncology's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on CG Oncology analyst ratings.
Get to Know CG Oncology Better
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology's Economic Impact: An Analysis
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: CG Oncology's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 3774.42%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: CG Oncology's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2629.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CG Oncology's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -6.45%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CG Oncology's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.12%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CG Oncology's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.